Close Menu
Beverly Hills Examiner

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    You either take the wheel, or were going to run into the wall: The founder who sold Wrike for $2.25 billion forced his engineers to build around AI | Fortune

    November 21, 2026

    Startup sues Apple in India over tap-to-share contacts feature | TechCrunch

    November 21, 2026

    The US to become first nation to fully shun a UN Human Rights Council review

    November 21, 2026
    Facebook X (Twitter) Instagram
    Beverly Hills Examiner
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • Lifestyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Terms and Conditions
      • Privacy Policy
    Beverly Hills Examiner
    Home»Science»What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know | WIRED
    Science

    What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know | WIRED

    By AdminJune 14, 2023
    Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
| WIRED

    [ad_1]

    That pig pancreas study was published in 1988. Were drug companies paying much attention then?

    Holst: I have always had friendly relationships with [Ozempic and Wegovy manufacturer] Novo Nordisk. It’s in Denmark, just up the street, and we were interested in the same things, so I kept telling them about what we were doing.

    They were obviously interested in anything that could stimulate insulin secretion, but I must say that when we showed Novo Nordisk that [a different but related hormone] does not stimulate insulin secretion in people with diabetes, they withdrew some research support we had received because they said it wouldn’t work.

    This is true. This is what happened. They were listening politely, but they weren’t really interested.

    But by the early 1990 things started to change?

    Holst: The real turning point was a study by Michael Nauck in 1993. We worked together, and we finally infused GLP-1 into people with type 2 diabetes and could show that the blood glucose came to completely normal levels in four hours, while insulin was stimulated and glucagon was inhibited. This demonstrated to everybody that this was really doing something in people with type 2 diabetes, completely unlike other hormones.

    At that point, did you have a sense of how much potential these drugs might have, for treating obesity as well as diabetes?

    Holst: We were finding these things out step by step. First, it was stimulating insulin secretion. That’s interesting but not really exciting. Then it’s stimulating glucagon secretion—that’s more interesting, put that on top. Then it’s also inhibiting the GI tract and gastric emptying.

    Then we find out it’s inhibiting food intake as well. Wow, amazing. Amazing. It’s building up on top of each other all the time.

    Joel Habener: We thought this might be a potential treatment for diabetes, type 2 diabetes. But we and others were finding with treating human subjects with GLP-1 in the very early days that you had to be very careful to keep the dose low, because many patients felt ill when they were eating. They were supposed to eat a meal, and then within 30 minutes we’d measure the blood insulin to check how effective it was.

    Many of the subjects noted they were unable to finish their meal. It was messing up the experimental protocol because they were getting full and feeling nauseated and saying they didn’t want to eat any more food. Today, we’re between 10 to 15 percent of adults in the world who have a BMI at or above 30; in the US it’s around 40 percent. And obesity is clearly a very serious metabolic disease.

    And that means a huge number of people will meet the FDA’s requirements for Wegovy treatment. Some projections put the future value of obesity drugs at $100 billion annually. Did you ever suspect that your work on GLP-1 could make you rich?

    Holst: I’m so old, you know! I’m from ’68 and all of that; I was walking around in the street with signs saying: “Research for the people, not for the profit.” We didn’t even think of patenting or getting money out of this or anything. We were interested in publishing, doing something and moving this ahead.

    [ad_2]

    Original Source Link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Previous ArticleMarvel Artist Was 93 – The Hollywood Reporter
    Next Article Apple MacBook Air (15-Inch, 2023) Review: Big Screen Love

    RELATED POSTS

    Voyager 1 Beat the Odds and Is Still Working a Light-Day Away From Earth

    November 18, 2026

    The Dark Side of the Moon Was the Brightest Part of 2026

    November 17, 2026

    Just 400 US Data Centers Use More Electricity Than Michigan

    November 16, 2026

    The EPAs Chemical-Detecting Plane Isnt Doing Its Job Anymore

    November 16, 2026

    Its Getting Too Dry for Even Cactuses to Survive

    November 15, 2026

    New Species of Giant Fungus Discovered in China Grows up to 20 Inches Tall

    November 15, 2026
    latest posts

    You either take the wheel, or were going to run into the wall: The founder who sold Wrike for $2.25 billion forced his engineers to build around AI | Fortune

    Andrew Filev wanted his engineers to move three times faster, so he built a machine…

    Startup sues Apple in India over tap-to-share contacts feature | TechCrunch

    November 21, 2026

    The US to become first nation to fully shun a UN Human Rights Council review

    November 21, 2026

    Bassam Tariq Says Marvels Scrapped Blade Reboot Taught Him Lifes Too Short to Make Sh** Films

    November 21, 2026

    Grimes Releases Two New Psy Opera Songs

    November 20, 2026

    Book Riots Deals of the Day for November 20, 2026

    November 20, 2026

    Chips can survive the space environment. Can their financing? | TechCrunch

    November 20, 2026
    Categories
    • Books (1,621)
    • Business (6,526)
    • Cover Story (17)
    • Film (6,460)
    • Lifestyle (4,501)
    • Music (6,536)
    • Politics (6,511)
    • Science (5,866)
    • Technology (6,463)
    • Television (6,157)
    • Uncategorized (3)
    • US News (6,509)
    popular posts

    New Godzilla Minus One Trailer Released

    [ad_1] The newest trailer for Godzilla Minus One has been released, showcasing more of the…

    Metallica Fan Shares ChatGPT Version of ‘Ride the Lightning’

    March 24, 2023

    The Hottest Startups in Berlin

    October 6, 2022

    How Connected Cars Can Map Urban Heat Islands

    June 27, 2022
    Archives
    Browse By Category
    • Books (1,621)
    • Business (6,526)
    • Cover Story (17)
    • Film (6,460)
    • Lifestyle (4,501)
    • Music (6,536)
    • Politics (6,511)
    • Science (5,866)
    • Technology (6,463)
    • Television (6,157)
    • Uncategorized (3)
    • US News (6,509)
    About Us

    We are a creativity led international team with a digital soul. Our work is a custom built by the storytellers and strategists with a flair for exploiting the latest advancements in media and technology.

    Most of all, we stand behind our ideas and believe in creativity as the most powerful force in business.

    What makes us Different

    We care. We collaborate. We do great work. And we do it with a smile, because we’re pretty damn excited to do what we do. If you would like details on what else we can do visit out Contact page.

    Our Picks

    Book Riots Deals of the Day for November 20, 2026

    November 20, 2026

    Chips can survive the space environment. Can their financing? | TechCrunch

    November 20, 2026

    AI stocks are selling off after Anthropics record IPO, and Wall Street is split on whether this is the top | Fortune

    November 20, 2026
    © 2026 Beverly Hills Examiner. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms & Conditions and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT